N/A
N=2,390
Lipid Management in Clinical Practice (MK-0524A-115)
Lipid Metabolism Disorder
Bottom Line
View on ClinicalTrials.gov: NCT01071278 ↗Enrolled (actual)
2,390
Serious AEs
0.8%
Results posted
Mar 2012
Primary outcome: Primary: Number of Participants With Lipid Panel Control — 249; 192; 245; 231 participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Merck Sharp & Dohme LLC
- Primary completion
- Feb 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Lipid Panel Control |
249; 192; 245; 231; 232; 194 | — |
| SECONDARY Number of Participants Who Reported Adverse Events |
1; 1; 1; 1; 1; 3 | — |
Summary
The aim of this observational program is to generate data on the use of Tredaptive (nicotinic acid/laropiprant) for lipid management under routine medical practice conditions.
Eligibility Criteria
Inclusion Criteria
- Patients are 18 years of age or older with lipid disorder treated with nicotinic acid/laropiprant
Exclusion Criteria
- Patient is currently participating in a clinical trial
Data sourced from ClinicalTrials.gov (NCT01071278). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.